Custom service

In Vitro Immunogenicity Risk Assessment

Assess immunogenicity risk of candidates before in-vivo commitment

Turnaround: 5–9 weeksTypical scale: µg – g sample scaleChemistry options: MHC-II presentation prediction; T-cell activation assays (PBMC); in-silico/ex-vivo combined scoring

The service is built around MHC-II presentation prediction. Depending on the molecule we may move to T-cell activation assays (PBMC) or in-silico/ex-vivo combined scoring to improve stability, loading or yield, and every batch is released with immunogenicity risk assessment report.

Because In Vitro Immunogenicity Risk Assessment projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.

Candidate ranking on immunogenicity risk

Deimmunization design support

Regulatory immunogenicity conclusions without clinical data

Samples requiring containment or licensing we do not hold (BSL-3, radioactive)

Analytical reports follow a fixed template: sample condition on receipt, method description with validation status, raw chromatograms and spectra, results with uncertainty, and an interpretation note. Urgent same-week slots are available for release-critical testing.

Service Highlights

  • MHC-II presentation prediction as the default route, with T-cell activation assays (PBMC) held as a proven fallback
  • In-silico/ex-vivo combined scoring worked into the design where the application requires it
  • Results are reported with detection limits and method validation status, so you know exactly what the number means
  • Analytical confirmation of every intermediate before the final release
  • Orthogonal methods are used by default — one measurement is an observation, two are data
  • Immunogenicity risk assessment report delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Sample intake & plan

    Samples are logged with chain of custody and the test matrix for In Vitro Immunogenicity Risk Assessment is confirmed.

  2. Method selection

    Analytical methods — MHC-II presentation prediction, T-cell activation assays (PBMC) — are chosen and their validation status documented.

  3. Measurement

    Testing is executed with system-suitability checks and orthogonal confirmation where required.

  4. Data review

    Chromatograms and spectra are reviewed by a second analyst before any result is issued.

  5. Reporting

    Immunogenicity risk assessment report is issued with detection limits and interpretation notes.

  6. Follow-up support

    We discuss anomalies and, where useful, propose the follow-up experiment that resolves them.

Specifications & timeline

Turnaround
5–9 weeks
Typical scale
µg – g sample scale
Chemistry options
MHC-II presentation prediction; T-cell activation assays (PBMC); in-silico/ex-vivo combined scoring
Deliverable
Immunogenicity risk assessment report
QC package
Method report, raw data, validated result with detection limits
Shipping
Blue ice or ambient by material; chain-of-custody on receipt

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.